Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small cell lung cancer (NSCLC), according to […]

BARCELONA – Adding preoperative chemoradiation to standard-of-care perioperative chemotherapy did not improve overall or progression-free survival in patients with resectable adenocarcinoma of the stomach or gastroesophageal […]

BARCELONA — In a first-in-human clinical trial, an investigational messenger RNA (mRNA)-based cancer vaccine for glioblastoma induced tumor-associated antigen-specific T-cell responses in more than three quarters […]

As the deadline nears for a Montana healthcare system to pay what has been called a “jaw-dropping” settlement of nearly $11 million dollars to resolve an […]

SAN DIEGO — The novel antibody-drug conjugate tusamitamab ravtansine (tusa rav, Sanofi) did not demonstrate greater efficacy than docetaxel in treating advanced nonsquamous non–small cell lung […]

Research offers promising insights into the ideal frontline therapies for mantle cell lymphoma (MCL), but there are continued unmet needs in the relapsed/refractory setting, blood cancer […]

HOUSTON — Chimeric antigen receptor T-cell therapy (CAR T) has emerged as a game changer for the treatment of multiple myeloma (MM), but questions remain as […]

The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response […]